Cpl Life Sciences US

US Staffing within Life Sciences

Close
  • Job Search
    • Physicians
    • Clinical Research
    • Regulatory Affairs
    • Send us your Resume
  • About Us
    • Meet The Team
    • Testimonials
    • Press
    • Contact Us
  • Industry Training
  • Client Services
    • Testimonials
  • Case Studies
  • My Account
Menu

Breast Cancer

Written by Cpl Life Sciences US
March 1, 2018

FDA supports early use of Lily’s breast cancer treatment, Verzenio

Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio – its third in five months – as it tries to chase down Pfizer’s category-leading Ibrance. The US regulator has given the nod to Verzenio for use in combination with an aromatase inhibitor as initial endocrine-based therapy for women with breast cancer

Continue Reading

Categories

  • Uncategorized
  • News
  • Career Advice
  • Company Info
  • Industry news

Tags

Abbvie achillion acquisitions advertising Alexion Allergan AstraZeneca Biosimilar Biotech BMS Boehringer Ingelheim Boston Breast Cancer Brexit clinical research Clinical Trial clinical trials CMO Conference CPL Physicians Diabetes drug development Elections Eli Lilly FDA Gene therapy Gilead graduate academy Hep C immuno-oncology J&J JnJ Networking Novartis Novo Nordisk oncology Parexel Pfizer Pharmaceutical Regulatory Roche Sandoz Sanofi Takeda US

Like to Talk to a Consultant?

Call or email us directly and find out your next career step:
info@cplphysicians.com or (617) 844-1434



Part of the Cpl Group

Expert Life Science Staffing

Contact Us

Call or email us to find out how we can assist you today

Call Us

Email Us

Our Offices

HEADQUARTERS
Cambridge, Boston,
Call: (617) 844-1434

UK
T: +44 (0)118 9522 799
BELGIUM
T: +32 (0)2 892 3993
GERMANY
T: +49 (0)711 222 54 403
IRELAND
T: +353 (0)144 752 96

© 2017 CPL Physicians — All Rights Reserved
Linked In Twitter Google
Back to Top